Department of Pathology, St Martin De Porres Hospital, No 565, Section 2, Daya Road, Chiayi 60069, Taiwan.
BMC Vet Res. 2011 Oct 21;7:62. doi: 10.1186/1746-6148-7-62.
α-Enolase (ENO1) is a key glycolytic enzyme implicated in the development of many human cancers including breast cancer. Increased expression of ENO1 has recently been reported in estrogen (ER)-positive human breast cancer patients. The present study examined the expression of ENO1 and assessed its significance in canine mammary carcinoma.
Immunohistochemical staining was employed to investigate the expression of ENO1 in 82 cases of canine mammary tumor (32 benign tumors and 50 carcinomas). Quantification of immunohistochemistry was carried out using Quick score and the results showed cytoplasmic ENO1 overexpression in 9 of the 50 carcinomas (18%). Overexpression of ENO1 correlated significantly with shorter cause-specific survival (P = 0.019), but was not associated with ER positivity in canine mammary carcinoma.
Our findings suggest that overexpression of ENO1 may be used as a prognostic marker for poor outcome in canine mammary carcinoma.
α-烯醇化酶（ENO1）是一种关键的糖酵解酶，与包括乳腺癌在内的许多人类癌症的发展有关。最近有报道称，ENO1 在雌激素（ER）阳性的人类乳腺癌患者中表达增加。本研究检测了 ENO1 的表达，并评估了其在犬乳腺肿瘤中的意义。
采用免疫组织化学染色法检测 82 例犬乳腺肿瘤（32 例良性肿瘤和 50 例癌）中 ENO1 的表达。采用 Quickscore 对免疫组化进行定量，结果显示在 50 例癌中 9 例（18%）存在细胞质 ENO1 过表达。ENO1 的过表达与特定原因的生存时间显著缩短相关（P=0.019），但与犬乳腺癌中的 ER 阳性无关。
我们的研究结果表明，ENO1 的过表达可用作犬乳腺癌预后不良的标志物。
